

PHARMA AIDS LIMITED
Statement of Financial Position (Un-audited)
As on December 31, 2025

| Particulars | Note | Amount in Taka | |
|--|-------|---------------------|--------------------|
| | | 31st December, 2025 | 30th June, 2025 |
| Assets | | | |
| Non-Current Assets: | | 142,934,792 | 93,770,520 |
| Property, Plant and Equipment (Annexure-D) | 2.00 | 142,934,792 | 93,770,520 |
| Current Assets: | | 494,777,979 | 487,167,132 |
| Inventories | 3.00 | 62,473,980 | 63,555,667 |
| Trade and Other Receivables | 4.00 | 200,730,755 | 184,156,546 |
| Advance, Deposit & Prepayments | 5.00 | 178,605,562 | 220,772,437 |
| L/C Margin & Others | 6.00 | 12,723,464 | 7,484,973 |
| Cash and Cash Equivalent | 7.00 | 40,244,218 | 11,197,509 |
| Total Assets | | 637,712,771 | 580,937,652 |
| Equity & Liabilities | | | |
| Shareholders' Equity: | | 466,569,057 | 432,359,304 |
| Issued Share Capital | 8.00 | 31,200,000 | 31,200,000 |
| Tax Holiday Reserve | | 2,867,808 | 2,867,808 |
| Revaluation Reserve | | 33,764,038 | 33,764,038 |
| CSR Fund | 9.00 | 2,727,604 | 2,238,408 |
| Retained Earnings | | 396,009,608 | 362,289,050 |
| Non-Current Liabilities: | | 2,586,998 | 2,188,483 |
| Deferred Tax Liability | 16.02 | 2,586,998 | 2,188,483 |
| Current Liabilities: | | 168,556,716 | 146,389,865 |
| Trade Payables | 10.00 | 3,829,451 | 3,881,057 |
| Loans & Advances | 11.00 | 16,797,950 | 17,694,741 |
| Short term loan | 12.00 | - | 9,603,277 |
| Liabilities for Expenses | 13.00 | 17,128,735 | 10,717,368 |
| Provision for Expenses | 14.00 | 30,172,960 | 28,338,667 |
| Unclaimed/Undistributed Dividend | 15.00 | 9,930,032 | 590,075 |
| Income Tax Payable | 16.00 | 81,690,197 | 68,573,850 |
| Liabilities for WPPF | 17.00 | 6,984,406 | 4,116,130 |
| Liabilities for Providend Fund | 18.00 | 2,022,985 | 2,874,700 |
| Total Equity & Liabilities | | 637,712,771 | 580,937,652 |
| NAV Per Share | 19.00 | 149.54 | 138.58 |


SHAHINOOR BABY
Chairperson


MUHIBUL HASSAN ADIL
Chief Financial Officer


FAIZUL HASSAN
Managing Director


SHAHINOOR BEGUM
Director


MD. HUMAYUN KABIR
Company Secretary



PHARMA AIDS LIMITED
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
for the 2nd Quarter ended on December 31, 2025

| Particulars | Note | Amount in Taka | | | |
|---|--------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| | | July 01, 2025 to Dec. 31, 2025 | July 01, 2024 to Dec. 31, 2024 | Oct. 01, 2025 to Dec. 31, 2025 | Oct. 01, 2024 to Dec. 31, 2024 |
| Net Sales Revenue | 21.00 | 261,414,471 | 225,018,035 | 142,278,639 | 121,279,387 |
| Cost of Goods Sold | 22.00 | (176,900,286) | (155,683,208) | (98,108,937) | (85,199,555) |
| Gross Profit | | 84,514,185 | 69,334,827 | 44,169,702 | 36,079,831 |
| Operating Expenses: | | | | | |
| Administrative and Selling Expenses | 23.00 | (23,078,229) | (21,302,811) | (12,695,909) | (11,320,267) |
| Profit from Operation | | 61,435,956 | 48,032,016 | 31,473,793 | 24,759,564 |
| Other Income | 24.00 | 127,189 | 639,611 | - | 51,687 |
| Financial Cost | 25.00 | (1,329,363) | (630,043) | (639,739) | (524,097) |
| Profit before Contribution to WPPF | | 60,233,782 | 48,041,584 | 30,834,054 | 24,287,155 |
| Contribution to WPPF | 17.00 | (2,868,275) | (2,287,694) | (1,468,288) | (1,156,531) |
| Profit before Tax | | 57,365,507 | 45,753,889 | 29,365,766 | 23,130,623 |
| Income Tax Expenses | 26.00 | (13,405,754) | (10,441,162) | (6,656,695) | (5,485,836) |
| Profit after Tax for the period | | 43,959,753 | 35,312,728 | 22,709,071 | 17,644,787 |
| Other Comprehensive Income | | | | | |
| Revaluation Surplus | | - | 35,919,189 | - | - |
| Deferred Tax on Revaluation Surplus | | - | (2,155,151) | - | - |
| Total Comprehensive Income | | 43,959,753 | 69,076,766 | 22,709,071 | 17,644,787 |
| Earning per Share (EPS) | 29.00 | 14.09 | 11.32 | 7.28 | 5.66 |
| Number of Shares used to compute EPS | | 3,120,000 | 3,120,000 | 3,120,000 | 3,120,000 |



SHAHINOOR BABY
Chairperson


FAIZUL HASSAN
Managing Director


SHAHINOOR BEGUM
Director


MUHIBUL HASSAN ADIL
Chief Financial Officer




MD. HUMAYUN KABIR
Company Secretary

PHARMA AIDS LIMITED

Statement of Changes in Equity (Un-audited)
for the 2nd Quarter ended on December 31, 2025


| Particulars | Share Capital | Tax Holiday Reserve | Revaluation Reserve | CSR Fund | Retained Earnings | Total |
|--|-------------------|---------------------|---------------------|------------------|--------------------|--------------------|
| Balance as on July 01, 2025 | 31,200,000 | 2,867,808 | 33,764,038 | 2,238,408 | 362,289,050 | 432,359,304 |
| Net profit for the period | - | - | - | - | 43,959,753 | 43,959,753 |
| CSR Fund Current period expenses | - | - | - | (390,000) | - | (390,000) |
| CSR Fund Provision @ 2% | - | - | - | 879,195 | (879,195) | - |
| Cash Dividend (2024-2025) | - | - | - | - | (9,360,000) | (9,360,000) |
| Balance as on December 31, 2025 | 31,200,000 | 2,867,808 | 33,764,038 | 2,727,603 | 396,009,608 | 466,569,057 |

Statement of Changes in Equity (Un-audited)
for the 2nd Quarter ended on December 31, 2024

| Particulars | Share Capital | Tax Holiday Reserve | Revaluation Reserve | CSR Fund | Retained Earnings | Total |
|--|-------------------|---------------------|---------------------|------------------|--------------------|--------------------|
| Balance as on July 01, 2024 | 31,200,000 | 2,867,808 | - | 1,227,107 | 307,550,278 | 342,845,193 |
| Net profit for the period | - | - | - | - | 35,312,728 | 35,312,728 |
| CSR Fund Current period expenses | - | - | - | (80,000) | - | (80,000) |
| Revaluation Surplus | - | - | 35,919,189 | - | - | 35,919,189 |
| Deferred Tax on Revaluation Surplus | - | - | (2,155,151) | - | - | - |
| CSR Fund Provision @ 2% | - | - | - | 706,255 | (706,255) | - |
| Cash Dividend (2023-2024) | - | - | - | - | (7,800,000) | (7,800,000) |
| Balance as on December 31, 2024 | 31,200,000 | 2,867,808 | 33,764,038 | 1,853,362 | 334,356,751 | 406,197,110 |


SHAHINOOR BABY
Chairperson


FAIZUL HASSAN
Managing Director


SHAHINOOR BEGUM
Director


MUHIBUL HASSAN ADIL
Chief Financial Officer




MD. HUMAYUN KABIR
Company Secretary

PHARMA AIDS LIMITED
Statement of Cash Flows (Un-Audited)
for the 2nd Quarter ended on December 31, 2025

| Particulars | Note | Amount in Taka | |
|---|--------------|--------------------------------------|--------------------------------------|
| | | July 01, 2025 to Dec. 31, 2025 | July 01, 2024 to Dec. 31, 2024 |
| A. Cash Flows from Operating Activities : | | | |
| Collection from Sales and others | | 244,967,451 | 190,249,462 |
| Payment to suppliers and others | | (200,885,692) | (162,803,631) |
| Tax paid | | (11,209,620) | (11,444,880) |
| Financial expense paid | | (1,329,363) | (630,043) |
| Net Cash Flows from Operating Activities | 31.00 | 31,542,776 | 15,370,908 |
| B. Cash Flows from Investing Activities : | | | |
| Acquisition of Fixed Assets | | (2,261,023) | (1,874,440) |
| Disposal of Fixed Assets | | - | 550,000 |
| Advance Against Land | | (215,000) | (13,431,838) |
| Advance against Building | | - | (694,750) |
| Net Cash Flows from Investing Activities | | (2,476,023) | (15,451,028) |
| C. Cash Flows from Financing Activities: | | | |
| Dividend Payment | | (20,043) | (545) |
| Net Cash Flows from Financing Activities | | (20,043) | (545) |
| Net Cash Inflows/(Outflows) | | 29,046,709 | (80,665) |
| D. Opening Cash & Cash Equivalent | | 11,197,509 | 32,723,348 |
| E. Closing Cash & Cash Equivalent | 7.00 | 40,244,218 | 32,642,684 |
| F. Net Operating Cash Flows Per Share (NOCFPS) | 30.00 | 10.11 | 4.93 |


SHAHINOOR BABY
Chairperson


MUHIBUL HASSAN ADIL
Chief Financial Officer


FAIZUL HASSAN
Managing Director




SHAHINOOR BEGUM
Director


MD. HUMAYUN KABIR
Company Secretary

PHARMA AIDS LIMITED
Notes to the Financial Statements (Un-Audited)
For the 2nd Quarter ended on December 31, 2025

| | Amount in Taka | |
|---|---------------------|--------------------|
| | 31st December, 2025 | 30th June, 2025 |
| 2.00 Property, Plant & Equipment | | |
| Cost/Revaluation: | | |
| Opening Balance | 249,547,406 | 209,950,225 |
| Additions during the year | 54,128,365 | 40,329,681 |
| Disposal during the period | - | (732,500) |
| Closing Balance | 303,675,771 | 249,547,406 |
| Depreciation: | | |
| Opening Balance | 155,776,886 | 149,828,037 |
| Charged during the year | 4,964,094 | 6,497,607 |
| Disposal during the period | - | (548,758) |
| Closing Balance | 160,740,980 | 155,776,886 |
| Written Down Value (WDV) | 142,934,792 | 93,770,520 |

Detail of addition of assets are shown in **Annexure-D** attached at the end.

3.00 Inventories

| | | |
|---------------------|-------------------|-------------------|
| Neutral Glass Tubes | 45,064,119 | 46,055,247 |
| Printing Materials | 13,841,399 | 13,645,152 |
| Packing Materials | 1,401,369 | 2,275,689 |
| Spare Parts | 662,500 | 439,080 |
| Finished Products | 1,504,593 | 1,140,498 |
| Total | 62,473,980 | 63,555,667 |

Inventories as on December 31, 2025, are valued at lower of average cost and net realizable value.

4.00 Trade & Other Receivable

| | | |
|--------------------------|--------------------|--------------------|
| Trade Receivables (4.01) | 177,486,804 | 160,912,594 |
| Other Receivables (4.02) | 23,243,951 | 23,243,951 |
| Total | 200,730,755 | 184,156,546 |

4.01 Respecting the privacy of the parties, schedule of Trade and Other Receivables cannot be shown. IAS 24 as per management decision. There is no security arrangement for receivables. Bad debt provision was made against Trade Receivables during the year (Note no. 14.00 & 23.00).
 Mentionable, few companies have suffered financially due to COVID-19 pandemic, geo-political conflict in Europe, and changes in top management. As a result, recovery of receivables from those companies has been difficult and uncertain in future. Hence, 2% of Trade Receivables is kept as provision for bad debt.

4.02 These amounts are unsecured, but good and being realized gradually in the ordinary course of business. No provision was made against Other Receivables for bad debt during the year under review.



[Signature]

| Amount in Taka | |
|---------------------|-----------------|
| 31st December, 2025 | 30th June, 2025 |

5.00 Advance, Deposits & Prepayments

5.01 Advance:

| | | |
|---------------------------|-------------------|--------------------|
| Advance Against Others | - | 409,654 |
| HN Consultancy Service | 100,000 | 100,000 |
| Prepaid VAT | 336,058 | 2,042,207 |
| Sunbird Trading Company | 2,425,000 | 2,425,000 |
| Advance against Land* | 49,690,000 | 49,475,000 |
| Advance against Machinery | - | 51,867,342 |
| Advance Against Building | 855,750 | 855,750 |
| CNG Supplier | - | 122,000 |
| VAT Software | 100,000 | 100,000 |
| Total | 53,506,808 | 107,396,953 |

* Invested against purchase of 49 decimal land owned by Late M.N.K. Aswad (Irrevocable Power Deed registered in favour of the Company) which was approved by the shareholders in the EGM, dated: 24/06/2024. Also includes costs related to registration, necessary permissions and legal vetting.

5.02 Security Deposits:

| | | |
|---|------------------|------------------|
| Titas Gas | 1,487,740 | 1,487,740 |
| BTCL for Telephone | 3,000 | 3,000 |
| Liquid oxygen supplier | 10,000 | 10,000 |
| Bangladesh Rural Electrification Board (BREB) | 382,804 | 382,804 |
| CDBL for DSE Server | 100,000 | 100,000 |
| Earnest Money | 4,289,300 | 3,675,650 |
| VAT Deposit (Excise Duty) | 451,472 | 451,472 |
| House Rent | 200,000 | 200,000 |
| Office Rent | 119,350 | 119,350 |
| Oxygen Cylinder | 400,000 | 400,000 |
| Oxygen Manifold | 80,000 | 80,000 |
| Total | 7,523,666 | 6,910,016 |

5.03 Prepayments:

| | | |
|--|--------------------|--------------------|
| AIT at Import Stage | 43,481,715 | 38,163,080 |
| AIT at Source | 72,993,373 | 67,302,387 |
| AIT paid in Cash | 1,100,000 | 1,000,000 |
| | 117,575,088 | 106,465,468 |
| Total Advance, Deposits & Prepayments | 178,605,562 | 220,772,437 |



262

6.00 L/C Margin and Others

Raw Materials : Glass Tubes

Total

| Amount in Taka | |
|---------------------|------------------|
| 31st December, 2025 | 30th June, 2025 |
| 12,723,464 | 7,484,973 |
| 12,723,464 | 7,484,973 |

7.00 Cash & Cash Equivalent**Cash in Hand (Note 7.01)****825,041****515,404****Cash at Bank (Note 7.02)**

Bangladesh Commerce Bank PLC., Principal Branch
 Al-Arafah Islami Bank PLC., V.I.P. Road Branch
 Pubali Bank PLC. ,Naya Paltan Branch
 Dutch Bangla Bank PLC., Foreign Exchange Branch
 Dutch Bangla Bank PLC., Bijoy Nagar Branch
 IFIC Bank PLC., Chandra Branch

| | |
|-------------------|-------------------|
| 17,662 | 56,671 |
| 28,103,532 | 9,570,216 |
| 621,183 | 352,721 |
| 144,090 | 144,090 |
| 9,684,623 | 558,030 |
| 848,087 | 377 |
| 39,419,177 | 10,682,105 |

Total Cash at Bank**40,244,218****11,197,509****Cash & Cash Equivalent**

7.01 The physical cash counting were taken place at the quarter end and found in order. Cash in hand has been verified by the Management at the closing of the quarter.

7.02 The Bank balance have been confirmed and reconciled with respective bank statements.

Effect of Foreign Exchange Rate Changes on Cash/Cash Equivalents:

The Company does not have any foreign currency account and does not do any export. 100% of finished goods are sold to the local pharmaceutical companies in local currency. Primary raw materials (glass tubes & color) are imported by sight L/C only, where payments are made at spot exchange rate mostly within 60-75 days from the L/C opening date. The Company never engages itself in forward booking of exchange rates and never holds any foreign currencies in hand or bank accounts. Therefore, effect of exchange rate changes on cash or cash equivalents is not applicable to the Company as per paragraph 28 of IAS 7 & 21.

8.00 Share Capital**Authorized Capital:**

5,000,000 Ordinary Shares @ Tk. 10 each

50,000,000**50,000,000****Issued, Subscribed & Paid up Capital:**

3,120,000 Ordinary Shares of Tk.10/- each paid-up in full

31,200,000**31,200,000**

| Amount in Taka | |
|---------------------|-----------------|
| 31st December, 2025 | 30th June, 2025 |

9.00 CSR Fund

| | | |
|---------------------------------------|------------------|------------------|
| Opening Balance | 2,238,408 | 1,227,107 |
| Current Period expenses | (390,000) | (265,000) |
| Provision for the current Period @ 2% | 879,195 | 1,276,301 |
| Closing Balance | 2,727,604 | 2,238,408 |

This represents balance of CSR Fund @2% of Net Profit after Income Tax which has been decided by the Board of Directors. It is shown in Shareholder's Equity as per IAS-1.

| | | |
|-----------------------------|------------------|------------------|
| 10.00 Trade Payables | 3,829,451 | 3,881,057 |
|-----------------------------|------------------|------------------|

It represents the amount payable to the suppliers of different items

11.00 Loans & Advances

| | | |
|--------------------------|--------------------|-------------------|
| Opening Balance | 17,694,741 | 1,200,099 |
| Addition during the year | 3,193,555 | 17,288,770 |
| Paid during the year | 20,888,296 | 18,488,869 |
| Closing Balance | (4,090,346) | (794,129) |
| | 16,797,950 | 17,694,741 |

12.00 Short term loan

| | | |
|------------------------|----------|------------------|
| Trust Receipt * | - | 9,603,277 |
|------------------------|----------|------------------|

* The Company has a short-term Trust Receipt (TR) facility against Letter of Credit (L/C) sanctioned by Al-Arafah Islami Bank Ltd. with a total limit of BDT 6 Crore (including 3 Crore inner TR limit).

13.00 Liabilities for expenses

| | | |
|--------------------------------|-------------------|-------------------|
| Salary/Remuneration/Honorarium | 1,365,239 | - |
| Gas Bill | 585,300 | 452,249 |
| Audit Fees | 3,375 | 235,750 |
| Incentive | 12,971,978 | 8,810,186 |
| Leave Pay | 11,397 | 11,397 |
| Electricity Bill | 1,068,736 | 15,250 |
| Water & Sewerage bill | 6,296 | 8,899 |
| AGM/EGM expense | 1,000 | 1,000 |
| Carriage Inward | 188,500 | 153,500 |
| VAT Payable | 694,645 | 799,037 |
| Security services | 51,269 | 39,100 |
| Interest on Loans | 150,000 | 160,000 |
| Other Expenses (CDBL) | 31,000 | 31,000 |
| Total | 17,128,735 | 10,717,368 |

14.00 Provision for expenses

| | | |
|----------|-------------------|-------------------|
| Gratuity | 26,623,224 | 25,120,415 |
| Bad debt | 3,549,736 | 3,218,252 |
| | 30,172,960 | 28,338,667 |



| | | Amount in Taka | |
|--------------|---|---------------------|-----------------|
| | | 31st December, 2025 | 30th June, 2025 |
| 15.00 | Unclaimed/Undistributed Dividend | | |
| | Opening Balance | 590,075 | 454,863 |
| | Add: Cash Dividend (FY 2024-2025) | 9,360,000 | 7,800,000 |
| | Less: Payment to Shareholders | (20,043) | (7,664,788) |
| | Less: Transferred to CMSF* | - | - |
| | Closing Balance (Note 15.01) | 9,930,032 | 590,075 |

*As per BSEC Directive No. BSEC/CMRRC/2021-386/03 dated January 14, 2021, till reporting date the Company has transferred a total sum of Tk.10,513,635.50 (from FY 1987-88 to FY 2019-20 which were overdue for more than 3 years) from its unclaimed/undistributed cash dividend account to Capital Market Stabilization Fund (CMSF) SND Account. Mentionable, the Company had also transferred a total of 77,750 unclaimed stock dividend to the CMSF B.O. Account during the FY 2021-2022. We have issued a cheque in favor of CMSF for the financial year 2020-2021 Tk. 212,731 (Cheque No-0784300, DBBL).

15.01 Year-wise Summary of Unclaimed/Undistributed Dividend as on December 31, 2025:

| Financial Year | Amount in BDT | Amount in BDT |
|----------------|------------------|----------------|
| 2020-2021 | 212,731 | 212,731 |
| 2021-2022 | 186,654 | 186,654 |
| 2022-2023 | 49,517 | 54,423 |
| 2023-2024 | 121,130 | 136,267 |
| 2024-2025 | 9,360,000 | - |
| Total | 9,930,032 | 590,075 |

16.00 Income Tax Payable

| | | |
|---------------------------------------|-------------------|-------------------|
| Opening Balance | 68,573,850 | 73,601,770 |
| Provision for the Period (Note 26.00) | 12,907,239 | 18,522,586 |
| Adjustment during the year | - | (23,550,506) |
| Employees Income Tax (Note 16.01) | 209,108 | - |
| Closing Balance | 81,690,197 | 68,573,850 |

16.01 Employees Income Tax

| | | |
|------------------------------------|----------------|-------------|
| Opening Balance | - | - |
| Deduction from salary | 1,316,848 | 2,601,991 |
| Payment/Adjusted during the period | (1,107,740) | (2,601,991) |
| Closing Balance | 209,108 | - |

16.02 Deferred tax liability/(Assets)

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax (expense)/income has been disclosed in Note 16.02.a. The components of deferred tax assets and liabilities are given below:

| Particulars | Carrying amount | Tax base value | Taxable (deductible) temporary difference | Applicable tax rate | Deferred tax liability/(assets) |
|--|--------------------|-------------------|---|---------------------|---------------------------------|
| Property, Plant & Equipment | 107,015,603 | 78,473,062 | 28,542,542 | 22.50% | 6,422,072 |
| Gratuity | 26,623,224 | - | (26,623,224) | 22.50% | (5,990,225) |
| Revaluation Surplus (Land) | 35,919,189 | - | 35,919,189 | 6% | 2,155,151 |
| Balance as on December 31, 2025 | 169,558,016 | 78,473,062 | 37,838,507 | - | 2,586,998 |
| Balance as on June 30, 2025 | 118,890,936 | 32,582,777 | 148,140 | - | 2,188,483 |



| Amount in Taka | |
|---------------------|-----------------|
| 31st December, 2025 | 30th June, 2025 |

16.02.a Deferred tax (Expense)/Income (at cost)

| | | |
|---|------------------|---------------|
| Opening balance of deferred tax liability | 33,331 | 48,387 |
| Closing balance of deferred tax liability | 431,847 | 33,331 |
| | <u>(398,515)</u> | <u>15,055</u> |

16.02b Deferred tax (Expense)/Income (Revaluation)

| | | |
|---|-------------|-------------|
| Opening balance of deferred tax liability | (2,155,151) | - |
| Closing balance of deferred tax liability | 2,155,151 | (2,155,151) |
| | - | (2,155,151) |

17.00 Liabilities for WPPF

| | | |
|------------------------------|------------------|------------------|
| Opening Balance | 4,116,130 | 4,228,237 |
| Provision for the year | 2,868,275 | 4,116,130 |
| Payment made during the year | - | (4,228,237) |
| Closing Balance | 6,984,406 | 4,116,130 |

18.00 Liabilities for Provident Fund

| | | |
|-------------------------|------------------|------------------|
| Opening balance | 2,874,700 | 1,921,954 |
| Employees' Contribution | 1,004,983 | 1,601,963 |
| Employer's Contribution | 467,539 | 882,273 |
| Interest | 175,763 | 322,027 |
| Payment | (2,500,000) | (1,853,517) |
| Closing Balance | 2,022,985 | 2,874,700 |

19.00 Net Assets Value (NAV) per share for the period calculated as follows

| | | |
|--|--------------------|--------------------|
| Total Assets | 637,712,771 | 580,937,652 |
| Less: Total Liabilities | (171,143,714) | (148,578,348) |
| Net assets | 466,569,057 | 432,359,304 |
| Weighted average number of ordinary shares | 3,120,000 | 3,120,000 |
| Net Assets Value (NAV) per share* | 149.54 | 138.58 |

*NAV has increased due to increase in retained earnings.

20.00 Related Party Transactions

| | | |
|----------------------------|------------------|------------------|
| Excelsior Corporation Ltd. | 1,024,567 | 1,024,567 |
| Closing Balance | 1,024,567 | 1,024,567 |



| Amount in Taka | |
|--------------------------------------|--------------------------------------|
| July 01, 2025 to Dec. 31, 2025 | July 01, 2024 to Dec. 31, 2024 |

21.00 Net Sales Revenue:

| | | |
|-------------------------|--------------------|--------------------|
| Gross Sales | 303,876,593 | 261,800,176 |
| Less: VAT | (39,636,077) | (34,147,849) |
| Less: Discount on Sales | (2,826,044) | (2,634,292) |
| Net Sales | 261,414,471 | 225,018,035 |

22.00 Cost of Goods Sold:

| | | |
|--|--------------------|--------------------|
| Raw Materials (Glass Tubes) | 96,698,238 | 84,801,796 |
| Printing Materials | 6,426,207 | 5,892,232 |
| Packing Materials | 7,120,874 | 6,074,068 |
| Spare Parts | 1,447,776 | 936,449 |
| Toll Charge | 7,848,372 | 7,963,207 |
| Salary & Wages | 17,711,557 | 15,955,328 |
| Bonus | - | 1,320 |
| Security Services | 246,829 | 204,000 |
| Fuel for Production | 576,320 | 565,250 |
| Electricity | 5,384,066 | 5,001,236 |
| Gas Consumption | 11,379,648 | 12,068,710 |
| Oxygen for Production | 7,148,409 | 6,029,301 |
| Factory Maintenance | 848,479 | 566,848 |
| Machine Maintenance | 318,177 | 450,028 |
| Staff benefit & Welfare | 2,430,057 | 2,176,685 |
| Renewal & Registration | 22,695 | - |
| Entertainment Expenses | 161,355 | 48,170 |
| Labour Charge | 151,562 | 103,827 |
| Depreciation | 4,513,877 | 2,723,079 |
| Telephone & Postage | 27,840 | 19,290 |
| Duties & Taxes | 56,830 | 137,753 |
| Conveyance Exp. | 118,377 | 82,712 |
| Printing & Stationery | 46,210 | 37,800 |
| Insurance (Fire) | 817,472 | 389,751 |
| Donation | - | 500 |
| Carriage Inward | 1,050,300 | 825,510 |
| Internet Bill | 6,930 | 6,930 |
| Incentive | 3,804,239 | 3,034,205 |
| Gratuity | 901,685 | 926,850 |
| Leave pay | - | 142,173 |
| Misc. Expenses | - | 2,144 |
| Total Cost of Goods Manufactured | 177,264,380 | 157,167,153 |
| Add: Opening Stock of Finished Goods | 1,140,498 | 449,527 |
| Less: Closing Stock of Finished Goods | 178,404,879 | 157,616,680 |
| Net Cost of Goods Sold | (1,504,593) | (1,933,472) |
| | 176,900,286 | 155,683,208 |

23.00 Administrative & Selling Expenses:

| | | |
|----------------------------------|------------|------------|
| AGM Expense | 96,585 | 66,560 |
| Salary & Remuneration/Honorarium | 14,086,562 | 13,633,509 |
| Conveyance | 105,825 | 94,667 |
| Entertainment | 134,583 | 118,864 |
| Office Rent | 768,164 | 773,065 |



| | Amount in Taka | |
|--|--------------------------------------|--------------------------------------|
| | July 01, 2025 to Dec. 31, 2025 | July 01, 2024 to Dec. 31, 2024 |
| House Rent | 520,000 | 500,000 |
| Printing & Stationery | 91,052 | 60,791 |
| Telephone & Postage | 58,093 | 45,700 |
| Carriage Outwards | 1,156,190 | 1,014,310 |
| Books & Periodicals | 12,718 | 15,176 |
| Tours & Travels | - | 24,250 |
| Renewal & Registration | 30,572 | 80,503 |
| Depreciation | 450,217 | 445,290 |
| Fuel for Vehicles | 310,550 | 297,780 |
| Vehicles Maintenance | 373,540 | 123,698 |
| Advertisement Exp. | 120,000 | 129,000 |
| Car Insurance | 71,268 | 78,006 |
| Canteen Subsidy | 339,917 | 148,135 |
| Business Promotion | 219,600 | 22,026 |
| Board Meeting fee | 112,500 | 60,000 |
| Office Maintenance | 162,775 | 237,039 |
| Legal expense | 50,000 | - |
| Internet Expenses | 41,286 | 35,286 |
| Software expenses | 12,000 | 12,000 |
| Electricity Bill | 219,678 | 212,394 |
| Water & Sewerage Bill | 21,067 | 42,070 |
| Incentive | 2,536,159 | 2,022,804 |
| Duties & Taxes | 37,220 | 26,638 |
| Gratuity | 601,124 | 617,900 |
| Bad debt expense | 331,484 | 356,419 |
| Misc. Expenses | 7,500 | 8,930 |
| Total Administrative & Selling Expenses | 23,078,229 | 21,302,811 |

24.00 Other Income:

| | | |
|------------------------------|----------------|----------------|
| Income from FDR Interest | 101,636 | 221,667 |
| Sale of Wastage (Note 24.01) | 25,553 | 51,686 |
| Gain on Disposal of Car | - | 366,258 |
| Total Other Income | 127,189 | 639,611 |

24.01 Sale of Wastage

| | | |
|-----------|---------------|---------------|
| Less: VAT | (6,190) | (13,966) |
| | 25,553 | 51,686 |

25.00 Financial Cost:

| | | |
|-----------------------------|------------------|----------------|
| Interest on Loans | 1,258,952 | 571,513 |
| Bank Charges | 70,411 | 58,530 |
| Total Financial Cost | 1,329,363 | 630,043 |

26.00 Income Tax Expenses

| | | |
|---|-------------------|---------------------|
| Current Tax Expense | 12,907,239 | (10,294,625) |
| Previous year tax expense | 100,000 | - |
| Deferred Tax Expense/Income (Note: 16.02.a) | 398,515 | (146,537) |
| | 13,405,754 | (10,441,162) |

i) Reconciliation of Effective Tax rate

| Types of Income | Income | 2025-2026 (Q2) | | 2024-2025 (Q2) | |
|-----------------------|------------|----------------|--------------------|----------------|--------------------|
| | | Tax Expense | Effective Tax Rate | Tax Expense | Effective Tax Rate |
| Net Profit before Tax | 57,365,507 | 12,907,239 | 22.50% | 10,294,625 | 22.50% |



[Signature]

| Amount in Taka | |
|--------------------------------------|--------------------------------------|
| July 01, 2025 to Dec. 31, 2025 | July 01, 2024 to Dec. 31, 2024 |

ii) Reconciliation of Current Tax (Expense)/Income

| Particulars | 2025-2026 (Q2) | 2024-2025 (Q2) |
|--|-------------------|-------------------|
| Net Profit before tax | 57,365,507 | 45,753,889 |
| Income tax rate @22.50% [A] | 12,907,239 | 10,294,625 |
| Income tax deducted at source U/S -163 (2) of ITA-2023 [B] | 5,690,986 | 5,799,687 |
| Minimum Tax U/S-163(5) of ITA-2023 @1% of Revenue[C] | 2,614,145 | 1,350,108 |
| Income tax Provision for the year: Higher of [A, B & C] | 12,907,239 | 10,294,625 |

27.00 Remuneration and other facilities for 4 Directors

| | | |
|-------------------------|------------------|------------------|
| Remuneration/Honorarium | 6,923,000 | 6,930,000 |
| House rent | 520,000 | 500,000 |
| | 7,443,000 | 7,430,000 |

28.00 Salary and other facilities for 7 Top Executives

| | | |
|--------|------------------|------------------|
| Salary | 6,063,000 | 5,758,000 |
| | 6,063,000 | 5,758,000 |

29.00 Basic Earnings Per Share (EPS):

| | | |
|----------------------------------|--------------|--------------|
| Net Profit after Tax | 43,959,753 | 35,312,728 |
| Number of ordinary shares | 3,120,000 | 3,120,000 |
| Earnings Per Share (EPS)* | 14.09 | 11.32 |

*EPS has increased compared to previous year's 2nd quarter mostly due to increase in sales, resulting from expansion of production capacity.

30.00 Net Operating Cash Flows Per Share (NOCFPS) :

Net Operating Cash Flows Per Share has been Calculated as follows:

| | | |
|---|--------------|-------------|
| Net Cash Flows from Operating Activities | 31,542,776 | 15,370,908 |
| Number of Ordinary shares | 3,120,000 | 3,120,000 |
| Net Operating Cash Flows Per Share (NOCFPS)* | 10.11 | 4.93 |

*NOCFPS increased due to increase in collection.



| Amount in Taka | |
|--------------------------------------|--------------------------------------|
| July 01, 2025 to Dec. 31, 2025 | July 01, 2024 to Dec. 31, 2024 |

31.00 Reconciliation from Net Profit to Net Operating Cash Flow: (December 31, 2025)

Disclosure with calculation: as per Clause 5(2)e of the BSEC Notification No. BSEC/CMRRC/2006-158/208/Admin/81 dated 20 June, 2018 :

| Particulars | July 01, 2025 to Dec. 31, 2025 | July 01, 2024 to Dec. 31, 2024 |
|---|--------------------------------------|--------------------------------------|
| Profit from Operation | 61,435,956 | 48,032,016 |
| Depreciation | 4,964,094 | 3,168,369 |
| Other Income | 127,189 | 273,353 |
| Financial Cost | (1,329,363) | (630,043) |
| Inventories (Increase)/Decrease | 1,081,687 | (26,090,263) |
| Trade and Other Receivables (Increase)/Decrease | (16,574,210) | (35,041,926) |
| Advance, Deposits & Prepayments (Increase)/Decrease | 1,624,153 | 919,635 |
| L/C Margin & Others (Increase)/Decrease | (5,238,491) | 15,785,710 |
| CSR Fund Payment | (390,000) | (80,000) |
| Trade Payable Increase/(Decrease) | (51,606) | (2,562,703) |
| Liabilities for expenses Increase/(Decrease) | 6,411,367 | 7,503,258 |
| Liabilities for Provident Fund Increase/(Decrease) | (851,715) | (135,394) |
| Provision for expense Increase/(Decrease) | 1,834,293 | (100,942) |
| Loans & Advances | (896,791) | 15,712,923 |
| Employee tax Liability Increase/(Decrease) | 209,108 | 219,001 |
| Short term loan Increase/(Decrease) | (9,603,277) | (157,206) |
| Tax paid | (11,209,620) | (11,444,880) |
| Total | 31,542,776 | 15,370,908 |



✓ 26/

PHARMA AIDS LIMITED
Schedule of Property, Plant & Equipment
As on December 31, 2025

Annexure-D

| SI No. | Category of Assets | Cost | | | Depreciation | | | Written down value as on 31-12-25 | | |
|-----------------------|-------------------------|------------------------|----------------------------|----------------------|----------------------|--------------|------------------------|-----------------------------------|----------------------|-------------|
| | | Balance as on 01-07-25 | Addition during the Period | Disposal/ Adjustment | Total as on 31-12-25 | Rate | Balance as on 01-07-25 | Charged during the Period | Disposal/ Adjustment | |
| 01 | Land | 80,811 | - | - | 80,811 | - | - | - | - | 80,811 |
| 02 | Building | 16,156,062 | 512,050 | - | 16,668,112 | 5% | 7,734,199 | 219,081 | - | 7,953,280 |
| 03 | Plant & Machinery | 169,175,481 | 52,786,788 | - | 221,962,269 | 10% | 127,408,832 | 4,067,057 | - | 131,475,890 |
| 04 | Air Compressor | 640,000 | - | - | 640,000 | 10% | 290,430 | - | - | 307,908 |
| 05 | Electrical Installation | 1,641,282 | 717,677 | - | 2,358,959 | 10% | 754,306 | 62,183 | - | 816,489 |
| 06 | Electrical Equipment | 561,679 | - | - | 561,679 | 10% | 458,196 | 5,174 | - | 463,370 |
| 07 | Office Equipment | 914,282 | 70,150 | - | 984,432 | 15% | 620,757 | 25,331 | - | 646,088 |
| 08 | Furniture & Fixture | 998,196 | 41,700 | - | 1,039,896 | 15% | 679,903 | 26,478 | - | 706,381 |
| 09 | Gas Line Installation | 701,845 | - | - | 701,845 | 10% | 618,320 | 4,176 | - | 622,496 |
| 10 | Oxygen Generator | 5,180,583 | - | - | 5,180,583 | 20% | 4,679,121 | 50,146 | - | 4,729,267 |
| 11 | Air Cooler | 868,141 | - | - | 868,141 | 20% | 625,147 | 24,299 | - | 649,446 |
| 12 | Mobile Scissor Lift | 483,447 | - | - | 483,447 | 20% | 340,872 | 14,257 | - | 355,130 |
| 13 | Motor Vehicles | 14,313,050 | - | - | 14,313,050 | 20% | 10,354,608 | 395,844 | - | 10,750,452 |
| 14 | Sundry Assets | 1,913,356 | - | - | 1,913,358 | 15% | 1,212,193 | 52,587 | - | 1,264,781 |
| Total 31-12-2025 (A1) | 213,628,217 | 54,128,365 | - | - | 267,756,582 | - | 155,776,885 | 4,964,094 | - | 160,740,979 |
| Total 30-06-2025 (A2) | 209,950,225 | 4,410,492 | 732,500 | 213,628,217 | 149,828,036 | 6,497,606.63 | 548,758 | 155,776,885 | 57,851,331 | 57,851,331 |

PHARMA AIDS LIMITED

Schedule of Property, Plant & Equipment (Revaluation Schedule)

As on December 31, 2025

| SI No. | Category of Assets | Revaluation | | | Depreciation | | | Written down value as on 31-12-25 | | |
|--------------------------|--------------------|------------------------|---------------------|----------------------|----------------------|-------------|------------------------|-----------------------------------|----------------------|-------------|
| | | Balance as on 01-07-25 | Revaluation Surplus | Disposal/ Adjustment | Total as on 31-12-25 | Rate | Balance as on 01-07-25 | Charged during the Period | Disposal/ Adjustment | |
| 01 | Land | 35,919,189 | - | - | 35,919,189 | - | - | - | - | 35,919,189 |
| Total 31-12-2025 (B1) | 35,919,189 | - | - | - | 35,919,189 | - | - | - | - | 35,919,189 |
| Total 30-06-2025 (B2) | - | 35,919,189 | - | - | 35,919,189 | - | - | - | - | 35,919,189 |
| Total 31-12-2025 (A1+B1) | 249,547,406 | 54,128,365 | - | - | 303,675,771 | - | 155,776,885 | 4,964,094 | - | 160,740,979 |
| Total 30-06-2025 (A2+B2) | 209,950,225 | 40,329,681 | 732,500 | 249,547,406 | - | 149,828,036 | 6,497,607 | 548,758 | 155,776,885 | 142,934,792 |

Depreciation Charge for the Period has been allocated as follows:

| | |
|------------------|------------------|
| 31-12-2025 | 30-06-2025 |
| 4,513,877 | 5,469,073 |
| 450,217 | 1,028,534 |
| 4,964,094 | 6,497,607 |

Manufacturing Overhead (Cost of Goods sold)
 Administrative & Selling Expenses



[Signature]